Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug (6/15/2022)

Written By Gary Mathias

Patent expands coverage to the world’s 2nd largest pharmaceutical market after the U.S.

Essex, CT – (June 15, 2022) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, announced that the China National Intellectual Property Administration has granted patent CN 109562186 providing composition of matter protection for TP-317. 

“TP-317 is a novel small molecule that represents a highly differentiated approach to regulating immune homeostasis with broad therapeutic potential in cancer and autoimmune diseases,” said Gary Mathias, co-founder and CEO of Thetis. “With long-term patents issued in the U.S., Europe, Japan and now China, TP-317 has the intellectual property foundation to support clinical development in all major markets.”

About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and chronic inflammatory diseases. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.

Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.  The SBIR Award (R44CA278026) is supported by the National Institute of Cancer of the National Institutes of Health (NIH). Statements regarding TP-317 and the SBIR Award are solely the responsibility of Thetis Pharmaceuticals LLC and do not represent the official views of the NIH.

Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com

Gary Mathias
Previous

Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug (8/24/2022)
Next

Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class, Oral Resolvin E1 Therapy for Crohn’s Disease (4/5/2022)